Russell Investments Group Ltd. decreased its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Rating) by 13.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 198,969 shares of the company’s stock after selling 31,878 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.40% of Protagonist Therapeutics worth $2,171,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. Point72 Hong Kong Ltd purchased a new position in shares of Protagonist Therapeutics during the 1st quarter valued at $135,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Protagonist Therapeutics by 18.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,536 shares of the company’s stock valued at $93,000 after acquiring an additional 1,337 shares during the last quarter. Quantbot Technologies LP bought a new stake in Protagonist Therapeutics in the 2nd quarter valued at $76,000. Jane Street Group LLC increased its holdings in Protagonist Therapeutics by 273.3% in the 3rd quarter. Jane Street Group LLC now owns 10,289 shares of the company’s stock valued at $87,000 after acquiring an additional 7,533 shares during the last quarter. Finally, Arizona State Retirement System bought a new stake in Protagonist Therapeutics in the 4th quarter valued at $113,000. Hedge funds and other institutional investors own 91.51% of the company’s stock.
Protagonist Therapeutics Stock Performance
Protagonist Therapeutics stock opened at $26.05 on Monday. The company’s 50-day moving average price is $22.73 and its 200-day moving average price is $15.69. Protagonist Therapeutics, Inc. has a twelve month low of $6.91 and a twelve month high of $26.87.
Wall Street Analysts Forecast Growth
A number of analysts have issued reports on the stock. JMP Securities reduced their price target on shares of Protagonist Therapeutics from $31.00 to $28.00 and set a “market outperform” rating on the stock in a report on Thursday, March 16th. StockNews.com assumed coverage on shares of Protagonist Therapeutics in a report on Thursday. They issued a “sell” rating on the stock. Finally, HC Wainwright lifted their price target on shares of Protagonist Therapeutics from $33.00 to $38.00 and gave the company a “buy” rating in a report on Thursday, March 16th.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
- Get a free copy of the StockNews.com research report on Protagonist Therapeutics (PTGX)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Want to see what other hedge funds are holding PTGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Rating).
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.